Skip to main content
Premium Trial:

Request an Annual Quote

Genomica Gets $7.5 Million to Build Business In Bioinformatics Software


BOULDER, Colo.--Genomica, a bioinformatics software company here, has received $7.5 million in initial funding to develop products for pharmaceutical, biotechnology, and agribusiness companies. The private investors include ARCH Venture Partners, Boulder Ventures, Falcon Technology Partners, Harris & Harris Group, INVESCO Trust, and Pegasus Technology Ventures. The software Genomica is developing offers such comprehensive, integrated bioinformatics tools as sequence, genetic, clinical, and functional analysis, and physical mapping. The company claims its software is unique in that it can maintain information on all aspects of the gene discovery process from clinical genetics work-up, to human genetics, genotyping, molecular cloning, and functional analysis of the gene sequence. The technology is compatible with UNIX, PC, and Macintosh systems.

In other news, Genomica--which opened for business last year--announced that Ralph Christoffersen, president and CEO of Ribozyme Pharmaceuticals, has joined its board of directors. He was previously a senior executive at SmithKline Beecham and Upjohn, and also served as president of Colorado State University.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.